Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305)

Abstract

Glioblastoma (GBM) is one of the worst cancers in terms of prognosis. Standard therapy consists of resection with concomitant chemoradiotherapy. Resistance to nimustine hydrochloride (ACNU), an alkylating agent, has been linked to methylguanine DNA methyltransferase (MGMT). Daily administration of procarbazine (PCZ) has been reported to decrease MGMT… (More)
DOI: 10.1007/s00280-012-2041-5

Topics

6 Figures and Tables

Cite this paper

@article{Shibui2012RandomizedTO, title={Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305)}, author={Soichiro Shibui and Yoshitaka Narita and Junki Mizusawa and Takaaki Beppu and K Ogasawara and Yutaka Sawamura and Hiroyuki Kobayashi and Ryo Nishikawa and Kazuhiko Mishima and Yoshihiro Muragaki and Takashi Maruyama and Jun-ichi Kuratsu and Hideo Nakamura and Masato Kochi and Yoshio Minamida and Toshiaki Yamaki and T Kumabe and Teiji Tominaga and Takamasa Kayama and Kaori Sakurada and Motoo Nagane and Keiichi Kobayashi and Hirohiko Nakamura and Tamio Ito and Takahito Yazaki and Hikaru Sasaki and Katsuyuki Tanaka and Hideaki Takahashi and A. Asai and Tomoki Todo and Toshihiko Wakabayashi and Jun Takahashi and Shingo Takano and Takamitsu Fujimaki and Minako Sumi and Yasuji Miyakita and Yoichi Nakazato and Akihiro Sato and Haruhiko Fukuda and Kazuhiro Nomura}, journal={Cancer Chemotherapy and Pharmacology}, year={2012}, volume={71}, pages={511-521} }